TCM Properties

Traditional Use

Clears Heat and resolves toxicity — folk use for febrile illness, sores, and abscesses
Hypoglycemic — folk use for diabetes mellitus
Antihypertensive — lowers blood pressure in traditional use
Anti-neoplastic — modern Chinese medicine use for cancer treatment (under medical supervision only)

Diuretic and anti-edematous in folk medicine
Source of four FDA-approved anticancer vinca alkaloids: vincristine, vinblastine, vindesine, vinorelbine

Chang Chun Hua (长春花, 'Eternal Spring Flower') is not a classical TCM herb — it is a modern addition to Chinese folk medicine, introduced from Madagascar and incorporated primarily for its antidiabetic and antihypertensive properties in 20th-century Chinese folk practice
Of primary pharmacological importance as the source plant for the vinca alkaloid class of anticancer drugs: vincristine (used in ALL, Hodgkin lymphoma, Wilms tumour) and vinblastine (Hodgkin disease, testicular cancer) were first isolated in the 1950s by Canadian and American researchers and are now on the WHO Essential Medicines List

Vincristine (monoterpene indole alkaloid; antimitotic — binds tubulin, prevents spindle formation)
Vinblastine (monoterpene indole alkaloid; antimitotic; structurally related to vincristine)
Vindesine and vinorelbine (semi-synthetic vinca alkaloid derivatives from plant-sourced precursors)
Catharanthine and tabersonine (precursor alkaloids; >100 alkaloids total identified)
Ajmalicine (antihypertensive alkaloid)
Serpentine (hypoglycemic alkaloid)

Anticancer via tubulin inhibition: vincristine and vinblastine block mitosis at metaphase by binding β-tubulin and preventing polymerisation into mitotic spindles; FDA-approved for haematological malignancies; sourced exclusively from C. roseus as chemical synthesis is not commercially viable (PMID 30256480)
Antidiabetic: serpentine and other alkaloids stimulate insulin release and inhibit glucose absorption — validated in rodent diabetic models; consistent with folk hypoglycemic use
Toxicity in uncontrolled ingestion: case report of C. roseus intoxication mimicking acute cholangitis — hepatotoxicity, GI symptoms, and neurological effects following unsupervised consumption (PMC10993546)

Unsupervised self-medication for any indication — HIGH RISK; alkaloid content requires controlled dosing
Pregnancy — embryotoxic and teratogenic; vinca alkaloids are Pregnancy Category D
Peripheral neuropathy (pre-existing) — vinca alkaloids worsen neuropathy
Concurrent chemotherapy without oncology supervision

SAFETY-CRITICAL: The whole plant contains vinca alkaloids at pharmacologically active concentrations. Unlike most TCM herbs, C. roseus is NOT suitable for casual folk self-treatment — therapeutic doses overlap with toxic doses
Neurotoxicity: peripheral neuropathy (sensory, motor, autonomic) is the primary dose-limiting toxicity of vinca alkaloids; reported even at sub-pharmaceutical doses with repeated exposure
SIADH risk: vinca alkaloids are associated with syndrome of inappropriate ADH secretion — hyponatremia reported
Hepatotoxicity: case reports of liver injury following unsupervised ingestion of plant preparations
Folk hypoglycemic use: if used, monitor blood glucose closely; additive effect with antidiabetic drugs
Standard folk dose (Chinese practice): 5–15g decoction — but this dose range carries unpredictable alkaloid delivery and is NOT recommended without medical supervision

Antineoplastic vinca alkaloids (vincristine, vinblastine, vinorelbine): additive toxicity — peripheral neuropathy, myelosuppression, SIADH; do not combine plant with pharmaceutical vinca alkaloids
Antidiabetic drugs (insulin, metformin, sulfonylureas): additive hypoglycemic effect via serpentine; monitor blood glucose
Antihypertensive drugs: additive blood pressure-lowering effect via ajmalicine; monitor for hypotension
CYP3A4 substrates: vinca alkaloids are CYP3A4 substrates and inhibitors; potential for complex bidirectional interactions with CYP3A4-metabolised medications
Neurotoxic drugs (platinum compounds, taxanes, thalidomide): additive peripheral neuropathy risk